Publication | Closed Access

Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial (075)

Cervical CancerPhase Ii TrialMedicineImmunologyPathologyImmune Checkpoint InhibitorAnti-pd-1/ctla4 Bi-specific AntibodyCancer TreatmentImmunotherapyOncologyRadiation Oncology